Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Data Sources and Search Strategy
Eligibility Criteria
2.2. Risk of Bias Assessment in Individual Studies
2.3. Summary Measures and Synthesis of Results
2.4. Risk of Bias Across Studies
3. Results
3.1. General Results
3.2. Study Characteristics
3.3. Definition of NAFLD
3.4. Serum Visfatin Levels in NAFLD vs. Controls
3.5. Serum Visfatin Levels in NASH vs. Controls
3.6. Serum Visfatin Levels in Simple Steatosis vs. Controls
3.7. Serum Visfatin Levels in NASH vs. Simple Steatosis
3.8. Serum Visfatin Levels in Simple Steatosis vs. Moderate Severe Steatosis
3.9. Serum Visfatin Levels in the Presence vs. Absence of Lobar Inflammation
3.10. Serum Visfatin Levels in the Presence vs. Absence of Liver Fibrosis
3.11. Serum Visfatin Levels in Males vs. Females
3.12. Quality Assessment
4. Discussion
5. Conclusions and Future Directions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Dumitrascu, D.L.; Neuman, M.G. Non-alcoholic fatty liver disease: An update on diagnosis. Clujul Med. 2018, 91, 147–150. [Google Scholar] [CrossRef] [Green Version]
- Sporea, I.; Popescu, A.; Dumitrașcu, D.; Brisc, C.; Nedelcu, L.; Trifan, A.; Gheorghe, L.; Braticevici, C.F. Nonalcoholic Fatty Liver Disease: Status Quo. J. Gastrointestin. Liver Dis. 2018, 27, 439–448. [Google Scholar] [CrossRef]
- Mantovani, A.; Scorletti, E.; Mosca, A.; Alisi, A.; Byrne, C.D.; Targher, G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020, 111, 154170. [Google Scholar] [CrossRef] [PubMed]
- Francque, S.M.; van der Graaff, D.; Kwanten, W.J. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J. Hepatol. 2016, 65, 425–443. [Google Scholar] [CrossRef] [Green Version]
- Blond, E.; Disse, E.; Cuerq, C.; Drai, J.; Valette, P.-J.; Laville, M.; Thivolet, C.; Simon, C.; Caussy, C. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: Do they lead to over-referral? Diabetologia 2017, 60, 1218–1222. [Google Scholar] [CrossRef] [Green Version]
- Patel, A.; Gawrieh, S.; Rizvi, S.; Xiang, Q.; Szabo, A.; Saeian, K. Management strategies used for nonalcoholic fatty liver disease: Survey of AASLD members. Gastroenterology 2009, 136, A847. [Google Scholar] [CrossRef]
- Chan, W.K.; Treeprasertsuk, S.; Imajo, K.; Nakajima, A.; Seki, Y.; Kasama, K.; Kakizaki, S.; Fan, J.-G.; Song, M.J.; Yoon, S.K.; et al. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region—The GO ASIA initiative. Aliment. Pharmacol. Ther. 2018, 47, 816–825. [Google Scholar] [CrossRef] [Green Version]
- Mirza, M.S. Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol. 2011, 2011, 592404. [Google Scholar] [CrossRef] [Green Version]
- Fang, Y.-L.; Chen, H.; Wang, C.-L.; Liang, L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model”. World J. Gastroenterol. 2018, 24, 2974–2983. [Google Scholar] [CrossRef]
- Funcke, J.B.; Scherer, P.E. Beyond adiponectin and leptin: Adipose tissue-derived mediators of inter-organ communication. J. Lipid Res. 2019, 60, 1648–1684. [Google Scholar] [CrossRef]
- Samal, B.; Sun, Y.; Stearns, G.; Xie, C.; Suggs, S.; Mcniece, I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell Biol. 1994, 14, 1431–1437. [Google Scholar] [CrossRef]
- Wang, T.; Zhang, X.; Bheda, P.; Revollo, J.R.; Imai, S.-I.; Wolberger, C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat. Struct. Mol. Biol. 2006, 13, 661–662. [Google Scholar] [CrossRef]
- Revollo, J.R.; Grimm, A.A.; Imai, S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 2004, 279, 50754–50763. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adolph, T.E.; Grander, C.; Grabherr, F.; Tilg, H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. Int. J. Mol. Sci. 2017, 18, 1649. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ognjanovic, S.; Bao, S.; Yamamoto, S.Y.; Garibay-Tupas, J.; Samal, B.; Bryant-Greenwood, G.D. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J. Mol. Endocrinol. 2001, 26, 107. [Google Scholar] [CrossRef] [Green Version]
- Duman, H.; Özyıldız, A.G.; Bahçeci, İ.; Duman, H.; Uslu, A.; Ergül, E. Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris. Ther. Adv. Cardiovasc. Dis. 2019, 13, 1–7. [Google Scholar] [CrossRef]
- Zheng, L.-Y.; Xu, X.; Wan, R.-H.; Xia, S.; Lu, J.; Huang, Q. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes. Diabetol. Metab. Syndr. 2019, 11, 60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hognogi, L.D.M.; Simiti, L.V. The cardiovascular impact of visfatin—An inflammation predictor biomarker in metabolic syndrome. Clujul Med. 2016, 89, 322–326. [Google Scholar] [CrossRef]
- Romacho, T.; Sánchez-Ferrer, C.F.; Peiró, C. Visfatin/Nampt: An adipokine with cardiovascular impact. Mediat. Inflamm. 2013, 2013, 946427. [Google Scholar] [CrossRef]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann. Intern. Med. 2009, 151, 264–269, w64. [Google Scholar] [CrossRef] [Green Version]
- Health NIo. Quality Assessment Tool for Observational Cohort and Cross-Sectional. Available online: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools2014 (accessed on 6 May 2020).
- Wallace, B.C.; Dahabreh, I.J.; Trikalinos, T.A.; Lau, J.; Trow, P.; Schmid, C.H. Closing the Gap between Methodologists and End-Users: R as a Computational Back-End. J. Stat. Softw. 2012, 49, 15. [Google Scholar] [CrossRef] [Green Version]
- Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. J. Stat. Softw. 2010, 36, 48. [Google Scholar] [CrossRef] [Green Version]
- Romanowska, A.; Lebensztejn, D.M. Evaluation of serum visfatin concentrations in children with nonalcoholic fatty liver disease. Pol. Merkur. Lek. Organ. Pol. Tow. Lek. 2010, 28, 459–461. [Google Scholar]
- Wen, H.; Wang, H.-J.; Dong, B.; Ma, J. Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease. Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua Liuxingbingxue Zazhi 2012, 33, 269–272. [Google Scholar] [PubMed]
- Cai, H.Y.; Li, Y.Z.; Li, L.; Tu, Q. Relationship between plasma visfatin and visceral fat thickness measured by ultrasonography in nonalcoholic fatty liver disease. World Chin. J. Dig. 2014, 22, 1564–1568. [Google Scholar] [CrossRef]
- Cai, H.Y.; Li, Y.Z.; Li, L.; Tu, Q. Clinical significance of plasma visfatin level in patients with non-alcoholic fatty liver disease. World Chin. J. Dig. 2014, 2763–2767. [Google Scholar] [CrossRef]
- Chwist, A.; Hartleb, M.; Lekstan, A.; Kukla, M.; Gutkowski, K.; Kajor, M. A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: A preliminary study. Pol. Arch. Med. Wewn. 2014, 124, 704–712. [Google Scholar] [CrossRef]
- Chernyak, O.O.; Sentsova, T.B.; Vorozhko, I.V.; Tutelyan, V.A.; Gapparova, K.M.; Isakov, V.A. Genomic, proteomic and metabolomic predictors of nonalcoholic fatty liver disease development in obese patients. Part. I. Vopr. Pitan. 2015, 84, 18–24. [Google Scholar] [PubMed]
- Salman, A.A.; Sultan, A.A.E.A.; Abdallah, A.; Abdelsalam, A.; Mikhail, H.M.S.; Tourky, M.; Omar, M.G.; Youssef, A.; Ahmed, R.A.; Elkassar, H.; et al. Effect of weight loss induced by laparoscopic sleeve gastrectomy on liver histology and serum adipokine levels. J. Gastroenterol. Hepatol. 2020. [Google Scholar] [CrossRef]
- Ooi, S.Q.; Chan, R.M.E.; Poh, L.K.S.; Loke, K.Y.; Heng, C.K.; Chan, Y.H.; Gan, S.U.; Lee, K.O.; Lee, Y.S. Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children. Pediatr. Obes. 2014, 9, 81–91. [Google Scholar] [CrossRef] [PubMed]
- Ding, B.J.; Guan, Y.H.; Li, J.; Wang, K.; Zhu, E.J.; Piao, Y.F. Single nucleotide polymorphisms of -3186 C>T in visfatin gene: Comparison between normal population and nonalcoholic fatty liver patients. J. Clin. Rehabil. Tissue Eng. Res. 2008, 12, 1345–1348. [Google Scholar]
- Aller, R.; de Luis, D.A.; Pacheco, D.; Velasco, M.C.; Conde, R.; Izaola, O.; González Sagrado, M. Influence of G1359A polimorphysm of the cannabinoid receptor gene (CNR1) on insulin resistance and adipokines in patients with non alcoholic fatty liver disease. Nutr. Hosp. 2012, 27, 1637–1642. [Google Scholar] [CrossRef]
- Waluga, M.; Kukla, M.; Żorniak, M.; Kochel-Jankowska, A.; Kajor, M.; Krzemiński, T.; Kotulski, R. Visfatin and TGF-Β1 in primary biliary cirrhosis and two other common liver diseases. Folia Med. Cracov. 2015, 55, 59–70. [Google Scholar] [PubMed]
- Jarrar, M.H.; Baranova, A.; Collantes, R.; Ranard, B.; Stepanova, M.; Bennett, C.; Fang, Y.; Elariny, H.; Goodman, Z.; Chandhoke, V.; et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008, 27, 412–421. [Google Scholar] [CrossRef] [PubMed]
- Younossi, Z.M.; Jarrar, M.; Nugent, C.; Randhawa, M.; Afendy, M.; Stepanova, M.; Rafiq, N.; Goodman, Z.; Chandhoke, V.; Baranova, A. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. 2008, 18, 1430–1437. [Google Scholar] [CrossRef]
- Aller, R.; De Luis, D.A.; Izaola, O.; Sagrado, M.G.; Conde, R.; Velasco, M.C.; Alvarez, T.; Pacheco, D.; González, J.M. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig. Dis. Sci. 2009, 54, 1772–1777. [Google Scholar] [CrossRef]
- Dahl, T.B.; Haukeland, J.W.; Yndestad, A.; Ranheim, T.; Gladhaug, I.P.; Damås, J.K.; Haaland, T.; Løberg, E.M.; Arntsen, B.; Birkeland, K.; et al. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2010, 95, 3039–3047. [Google Scholar] [CrossRef]
- Gaddipati, R.; Mitnala, S.; Padaki, N.; Mukherjee, R.M.; Sekaran, A.; Jayaraj-Mansard, M.; Rabella, P.; Rao-Guduru, V.; Reddy-Duwuru, N. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann. Hepatol. 2010, 9, 266–270. [Google Scholar] [CrossRef]
- Kukla, M.; Ciupińska-Kajor, M.; Kajor, M.; Wylezoł, M.; Zwirska-Korczala, K.; Hartleb, M.; Berdowska, A.; Mazur, W. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol. J. Pathol. 2010, 61, 147–153. [Google Scholar]
- Akbal, E.; Koçak, E.; Taş, A.; Yüksel, E.; Köklü, S. Visfatin Levels in Nonalcoholic Fatty Liver Disease. J. Clin. Lab. Anal. 2012, 26, 115–119. [Google Scholar] [CrossRef]
- Yoon, M.Y.; Sung, J.M.; Song, C.S.; Lee, W.Y.; Rhee, E.J.; Shin, J.H.; Yoo, C.H.; Chae, S.W.; Kim, J.Y.; Jin, W.; et al. Enhanced A-FABP expression in visceral fat: Potential contributor to the progression of NASH. Clin. Mol. Hepatol. 2012, 18, 279–286. [Google Scholar] [CrossRef]
- Auguet, T.; Terra, X.; Porras, J.A.; Orellana-Gavaldà, J.M.; Martinez, S.; Aguilar, C.; Lucas, A.; Pellitero, S.; Hernández, M.; Del Castillo, D.; et al. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. Clin. Biochem. 2013, 46, 202–208. [Google Scholar] [CrossRef] [PubMed]
- Genc, H.; Dogru, T.; Kara, M.; Tapan, S.; Ercin, C.N.; Acikel, C.; Karslioglu, Y.; Bagci, S. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann. Hepatol. 2013, 12, 380–387. [Google Scholar] [CrossRef]
- Polyzos, S.A.; Kountouras, J.; Papatheodorou, A.; Katsiki, E.; Patsiaoura, K.; Zafeiriadou, E.; Zavos, C.; Papadopoulou, E.; Terpos, E. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. Ann. Hepatol. 2013, 12, 749–757. [Google Scholar] [CrossRef]
- Jamali, R.; Arj, A.; Razavizade, M.; Aarabi, M.H. Prediction of nonalcoholic fatty liver disease via a novel panel of serum adipokines. Medicine 2016, 95. [Google Scholar] [CrossRef]
- Jamali, R.; Hatami, N.; Kosari, F. The correlation between serum adipokines and liver cell damage in non-alcoholic fatty liver disease. Hepat. Mon. 2016, 16. [Google Scholar] [CrossRef] [Green Version]
- Jamali, R.; Razavizade, M.; Arj, A.; Aarabi, M.H. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease. World J. Gastroenterol. 2016, 22, 5096–5103. [Google Scholar] [CrossRef] [PubMed]
- Amirkalali, B.; Sohrabi, M.; Rahimi-Moghaddam, P.; Esrafily, A.; Gholami, A.; Hosseinzadeh, P.; Keyvani, H.; Shidfar, F.; Zamani, F. The association of nicotinamide phosphoribosyltransferase polymorphism with markers of hepatic injury and de novo lipogenesis in nonalcoholic fatty liver disease. Hepat. Mon. 2017, 17. [Google Scholar] [CrossRef] [Green Version]
- Amirkalali, B.; Sohrabi, M.R.; Esrafily, A.; Jalali, M.; Gholami, A.; Hosseinzadeh, P.; Keyvani, H.; Shidfar, F.; Zamani, F. Association between Nicotinamide Phosphoribosyltransferase and de novo Lipogenesis in Nonalcoholic Fatty Liver Disease. Med. Princ. Pract. 2017, 26, 251–257. [Google Scholar] [CrossRef] [PubMed]
- Amirkalali, B.; Sohrabi, M.R.; Gholami, A.; Hosseinzadeh, P.; Shidfar, F.; Zamani, F. Interpretation of serum visfatin level in relation to hepatic injury is probably gender dependent in nonalcoholic fatty liver disease. Hepat. Mon. 2017, 17. [Google Scholar] [CrossRef] [Green Version]
- Mousavi, Z.; Ganji, A.; Farrokh Tehrani, D.; Bahari, A.; Esmaeil Zadeh, A.; Delghandi, M. Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome. Med. J. Islam. Repub. Iran. 2017, 31, 28. [Google Scholar] [CrossRef] [Green Version]
- Elkabany, Z.A.; Hamza, R.T.; Ismail, E.A.R.; Elsharkawy, A.; Yosry, A.; Musa, S.; Khalaf, M.A.; Elgawesh, R.M.; Esmat, G. Serum visfatin level as a non-invasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: Relation to transient elastography with controlled attenuation parameter. Eur. J. Gastroenterol. Hepatol. 2019. [Google Scholar] [CrossRef]
- Johannsen, K.; Flechtner-Mors, M.; Kratzer, W.; Koenig, W.; Boehm, B.O.; Schmidberger, J. Association between Visfatin and Hepatic Steatosis in the General Population during Long-Term Follow-Up. Horm. Und. Stoffwechs. Horm. Et Metab. Horm. Metab. Res. 2019. [Google Scholar] [CrossRef]
- Qiu, Y.; Wang, S.F.; Yu, C.; Chen, Q.; Jiang, R.; Pei, L.; Huang, Y.L.; Pang, N.Z.; Zhang, Z.; Ling, W.; et al. Association of circulating adipsin, visfatin, and adiponectin with nonalcoholic fatty liver disease in adults: A case-control study. Ann. Nutr. Metab. 2019, 74, 44–52. [Google Scholar] [CrossRef] [PubMed]
- Polyzos, S.A.; Kountouras, J.; Mantzoros, C.S. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016, 65, 1062–1079. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boutari, C.; Perakakis, N.; Mantzoros, C.S. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinol. Metab. 2018, 33, 33–43. [Google Scholar] [CrossRef]
- Bekaert, M.; Verhelst, X.; Geerts, A.; Lapauw, B.; Calders, P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: A systematic review. Obes. Rev. 2016, 17, 68–80. [Google Scholar] [CrossRef] [Green Version]
- Eslam, M.; Newsome, P.N.; Anstee, Q.M.; Targher, G.; Gomez, M.R.; Zelber-Sagi, S.; Wong, V.W.; Dufour, J.F.; Schattenberg, J.; Arrese, M.; et al. A new definition for metabolic associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020. [Google Scholar] [CrossRef]
- Eslam, M.; Sanyal, A.J.; George, J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020. [Google Scholar] [CrossRef]
- Leoni, S.; Tovoli, F.; Napoli, L.; Serio, I.; Ferri, S.; Bolondi, L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J. Gastroenterol. 2018, 24, 3361–3373. [Google Scholar] [CrossRef]
- Ismaiel, A.; Leucuta, D.C.; Popa, S.L.; Fagoonee, S.; Pellicano, R.; Abenavoli, L.; Dumitrascu, D.L. Non-invasive biomarkers in predicting non-alcoholic steatohepatitis and assessing liver fibrosis: Systematic review and meta-analysis. Panminerva Med. 2020. [Google Scholar] [CrossRef]
- Dyson, J.K.; Anstee, Q.M.; McPherson, S. Non-alcoholic fatty liver disease: A practical approach to diagnosis and staging. Frontline Gastroenterol. 2014, 5, 211–218. [Google Scholar] [CrossRef]
- Targher, G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: The plot thickens. Diabet. Med. 2007, 24, 1–6. [Google Scholar] [CrossRef]
- Ninomiya, S.; Shimizu, M.; Imai, K.; Takai, K.; Shiraki, M.; Hara, T.; Tsurumi, H.; Ishizaki, S.; Moriwaki, H. Possible Role of Visfatin in Hepatoma Progression and the Effects of Branched-Chain Amino Acids on Visfatin-Induced Proliferation in Human Hepatoma Cells. Cancer Prev. Res. 2011, 4, 2092–2100. [Google Scholar] [CrossRef] [Green Version]
- Pazgan-Simon, M.; Kukla, M.; Zuwała-Jagiełło, J.; Derra, A.; Bator, M.; Menżyk, T.; Lekstan, A.; Grzebyk, E.; Simon, K. Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC). PLoS ONE 2020, 15, e0227459. [Google Scholar] [CrossRef] [Green Version]
- Tsai, I.T.; Wang, C.-P.; Yu, T.-H.; Lu, Y.-C.; Lin, C.-W.; Lu, L.-F.; Wu, C.-C.; Chung, F.-M.; Lee, Y.-J.; Hung, W.-C.; et al. Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection. Cytokine 2017, 90, 54–59. [Google Scholar] [CrossRef] [PubMed]
- Liang, N.; Chen, Y.; Yang, L.; He, S.; Liu, T. Visfatin increases miR-21 to promote migration in HCC. Cell Mol. Biol. 2018, 64, 48–52. [Google Scholar] [CrossRef] [PubMed]
- Catalán, V.; Gómez-Ambrosi, J.; Rodríguez, A.; Pérez-Hernández, A.I.; Gurbindo, J.; Ramírez, B.; Méndez-Giménez, L.; Rotellar, F.; Valentí, V.; Moncada, R.; et al. Activation of Noncanonical Wnt Signaling Through WNT5A in Visceral Adipose Tissue of Obese Subjects Is Related to Inflammation. J. Clin. Endocrinol. Metab. 2014, 99, E1407–E1417. [Google Scholar] [CrossRef] [Green Version]
- Targher, G.; Day, C.P.; Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010, 363, 1341–1350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ismaiel, A.; Colosi, H.A.; Rusu, F.; Dumitrascu, D.L. Cardiac Arrhythmias and Electrocardiogram Modifications in Non-Alcoholic Fatty Liver Disease. A Systematic Review. J. Gastrointestin. Liver Dis. 2019, 28, 483–493. [Google Scholar] [CrossRef] [PubMed]
- Byrne, C.D.; Targher, G. NAFLD: A multisystem disease. J. Hepatol. 2015, 62, S47–S64. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vecchié, A.; Dallegri, F.; Carbone, F.; Bonaventura, A.; Liberale, L.; Portincasa, P.; Frühbeck, G.; Montecucco, F. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur. J. Intern. Med. 2018, 48, 6–17. [Google Scholar] [CrossRef] [PubMed]
- Hernaez, R.; Lazo, M.; Bonekamp, S.; Kamel, I.; Brancati, F.L.; Guallar, E.; Clark, J.M. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology 2011, 54, 1082–1090. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dasarathy, S.; Dasarathy, J.; Khiyami, A.; Joseph, R.; Lopez, R.; McCullough, A.J. Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. J. Hepatol. 2009, 51, 1061–1067. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ismaiel, A.; Leucuta, D.-C.; Popa, S.-L.; Dumitrascu, D.L. Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis. J. Clin. Med. 2021, 10, 3029. https://doi.org/10.3390/jcm10143029
Ismaiel A, Leucuta D-C, Popa S-L, Dumitrascu DL. Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2021; 10(14):3029. https://doi.org/10.3390/jcm10143029
Chicago/Turabian StyleIsmaiel, Abdulrahman, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, and Dan L. Dumitrascu. 2021. "Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis" Journal of Clinical Medicine 10, no. 14: 3029. https://doi.org/10.3390/jcm10143029
APA StyleIsmaiel, A., Leucuta, D.-C., Popa, S.-L., & Dumitrascu, D. L. (2021). Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 10(14), 3029. https://doi.org/10.3390/jcm10143029